A randomized, double-blind, placebo-controlled, phase III study comparing the combination of PDR001, D and T versus placebo, D and T in previously untreated patients with unresectable or metastatic BRAF V600–mutant melanoma (COMBI-i)

Home / Abstract / A randomized, double-blind, placebo-controlled, phase III study comparing the combination of PDR001, D and T versus placebo, D and T in previously untreated patients with unresectable or metastatic BRAF V600–mutant melanoma (COMBI-i)